Leap Therapeutics, Inc. LPTX
We take great care to ensure that the data presented and summarized in this overview for LEAP THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LPTX
View allLatest Institutional Activity in LPTX
Top Purchases
Top Sells
About LPTX
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Insider Transactions at LPTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 13
2024
|
Douglas E Onsi CEO,CFO,Pres.,GC,Treas.&Sec. |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,136
+0.31%
|
$4,272
$2.82 P/Share
|
|
Nov 13
2024
|
James H Cavanaugh Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
213
+50.0%
|
$426
$2.82 P/Share
|
|
Nov 13
2024
|
Christopher Mirabelli Chairman of the Board |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,136
+0.31%
|
$4,272
$2.82 P/Share
|
|
Nov 13
2024
|
Augustine Lawlor Chief Operating Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,136
+0.31%
|
$4,272
$2.82 P/Share
|
|
Jan 26
2024
|
John Mark O'Mahony Chief Manufacturing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jan 26
2024
|
Christopher Mirabelli Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.57%
|
-
|
|
Jan 26
2024
|
Douglas E Onsi CEO,CFO,Pres.,GC,Treas.&Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+9.24%
|
-
|
|
Jan 26
2024
|
Augustine Lawlor Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.57%
|
-
|
|
Jan 26
2024
|
Cynthia Sirard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Mar 17
2023
|
Douglas E Onsi CEO,CFO,Pres.,GC,Treas.&Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
660,606
+49.97%
|
-
|
|
Sep 24
2021
|
Bei Gene, Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,543,800
+25.72%
|
$5,087,600
$2.85 P/Share
|
|
Dec 28
2020
|
Health Care Ventures Viii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,618,406
-100.0%
|
-
|
|
Jun 22
2020
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,750,000
+17.11%
|
$3,500,000
$2.0 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 27.5K shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 6.62K shares |